Consistent with the effect on AMPK and ACC, OA treatment significantly reduced the levels of mature SREBP-1c (mSREBP-1c by 58%), FAS (by 50%) and SCD-1 (by 61%) (all p<0.05 vs. T2D mice, Fig. 5A). This evidence concerns the gene SREBF1 and type 2 diabetes mellitus.